Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	March 14, 2024
Length of Meeting:	2 hours and 32 minutes
Location of Meeting:	DMAS Board Room 102

Members Present:
Rachel Cain, PharmD, Chair
Denise Lowe, PharmD
Elizabeth Gaughan, MD, Vice-Chair
Jack Weisskohl, NP
Kristi Fowler, RPh
Matthew Estes, PharmD
Melissa Chouinard, MD

Members Not Present:
Denese Gomes, NP
Michele Thomas, PharmD
Seth Brant, MD
Wendy Nash, PharmD

DMAS Attendees:
Lisa Price Stevens, MD, MPH, MBA, FACP, CHIE, Chief Medical Officer
MaryAnn McNeil, RPh, Pharmacy Manager
JoeMichael Fusco, PharmD, MCO Pharmacy Compliance Manager
Kiara Jasper, MHA, CPhT, Pharmacy Systems Administrator

Contractors:
Debbie Moody, RPh, Director, Clinical Account Services, Prime Therapeutics
Nancy Eldin, PharmD, Pharmacist Account Executive, Prime Therapeutics
David D'Amico, PharmD, Pharmacist Account Executive, Prime Therapeutics
Jeni Hodzic, CPhT, Senior Account Management Specialist, Prime Therapeutics

Visitors:
Brian Trentler
Caroline Faber
Joe Kupiec
Katherine Klem
Laurie Mauthe
Lisa Barefoot
Norma Moledo
Scott Burns
Shantel Gooden

Call to Order and Introductions

Dr. Rachel Cain welcomed and thanked everyone for attending the DUR meeting.

Dr. Cain called the meeting to order at 1:00 pm.

Minutes – December 14, 2023

Dr. Melissa Chouinard motioned to approve the December 14, 2023 meeting minutes as submitted. Dr. Denise Lowe seconded the motion.

Review Members and Nominations

Nominations for DUR Chair and DUR Vice Chair were discussed.

- For DUR Chair
  - Kristi Fowler nominated Dr. Cain for Chair and Dr. Matthew Estes seconded.
  - Dr. Chouinard motioned to approve Dr. Cain as Chair and Ms. Fowler seconded.

- For DUR Vice Chair
  - Dr. Cain nominated Dr. Elizabeth Gaughan for Vice Chair and Ms. Fowler seconded.
  - Dr. Chouinard motioned to approve Dr. Gaughan as Vice Chair and Dr. Cain seconded.

New Drugs

The DUR Board reviewed Augtyro™ (repotrectinib), Fruzaqla™ (fruquintinib), Iwilfin™ (eflornithine), Ogsiveo™ (nirogacestat), Truqap™ (capivasertib) and Wainua™ (eplontersen). The Impact Reports and the report for the utilization of these six new DUR drugs for Fee-For-Service (FFS) and Managed Care Organizations (MCOs) were reviewed. The gender question on all new and existing service authorization (SA) criteria/fax forms will be removed. The DUR Board is interested in doing an audit and looking at the utilization of the oral oncology drugs. The board agreed that the first oral oncology class of drugs to do this audit on are the lung cancer drugs and to look back 6 months.

The DUR Board reviewed the current SA class criteria for Oral Oncology – Lung Cancer and Other Neoplasm Drugs. The board discussed to update question number 6 to state “Is the member free from unacceptable toxicity?”. New updates in reference to indications and minimum age from each drug’s package insert has been included. After

discussion by the board, Ms. Fowler motioned to accept the SA criteria with the following new updates: add the new drug Augtyro™ to the SA criteria along with the FDA approved indications and minimum age; update question number 6 to “Is the member free from unacceptable toxicity?”.; and include any new updates in reference to indications and minimum age from each drug’s package insert. Dr. Chouinard seconded the motion.

The DUR Board reviewed the current SA class criteria for Oral Oncology – Other Cancer and Other Neoplasm Drugs. The board discussed to update question number 6 to state “Is the member free from unacceptable toxicity?”. New updates in reference to indications and minimum age from each drug’s package insert has been included. After discussion by the board, Dr. Chouinard motioned to accept the SA criteria with the following new updates: add the new drugs Fruzaqla™, Iwilfin™ and Ogsiveo™ to the SA criteria along with the FDA approved indications and minimum age; update question number 6 to “Is the member free from unacceptable toxicity?”.; and include any new updates in reference to indications and minimum age from each drug’s package insert.

- Fruzaqla™ vote - Dr. Estes seconded the motion.
- Iwilfin™ vote - Dr. Gaughan seconded the motion.
- Ogsiveo™ vote - Dr. Estes seconded the motion.

The DUR Board reviewed the current SA class criteria for Oral Oncology – Breast Cancer and Other Neoplasm Drugs. The board discussed to update question number 6 to state “Is the member free from unacceptable toxicity?”. New updates in reference to indications and minimum age from each drug’s package insert has been included. After discussion by the board, Dr. Chouinard motioned to accept the SA criteria with the following new updates: add the new drug Truqap™ to the SA criteria along with the FDA approved indications and minimum age; update question number 6 to “Is the member free from unacceptable toxicity?”.; and include any new updates in reference to indications and minimum age from each drug’s package insert. Dr. Gaughan seconded the motion.

The DUR Board reviewed the SA criteria for Wainua™. After discussion by the DUR Board, Dr. Chouinard motioned to accept the SA criteria with the following new updates: remove in question number 1 the examples of allowed specialist (e.g., cardiologist, geneticist, neurologist) and update question number 10 to state “Is the member free from unacceptable toxicity?”. Dr. Gaughan seconded the motion.

Old Business

The DUR Board reviewed the SA criteria for Cuvrior™. After discussion by the DUR Board, Dr. Estes motioned to have no SA criteria for Cuvrior™. Dr. Chouinard seconded the motion.

Hepatitis C Compliance - At the December 2023 meeting, the members requested the data be re-examined to look at the 30% deemed not compliant and those members' eligibility. Dr. Cain shared that one of the MCO pharmacy directors requested the Hepatitis C compliance data for their MCO to review by their MCO's DUR Board. The data has been collected for each MCO and submitted to the individual MCO pharmacy directors to review, follow up on their patients and provide outcomes to DMAS.

The DUR Board reviewed reports in reference to the follow-up for members on concurrent opioids and benzodiazepines; concurrent opioids and antipsychotics; or overlaps in opioids, benzodiazepines, and antipsychotics. The DUR Board requested in the future when looking at these reports to add quantity filled, days supply, dates of fills/refills, detailed pharmacy and medical practice information to see if these are coming from the same pharmacy or same medical practice. Also, research the meaning behind the taxonomy description "student in an organized health care education/training program/student, health care". The DUR Board is also interested in bringing back the opioid report which also checks if the member has a prescription for buprenorphine or naloxone drugs.

Prime Therapeutics Pipeline and DUR Quarterly Newsletter- The January 2024 Prime Therapeutics Pipeline Report and the December 2023 DUR Quarterly Newsletter were both available on the DUR Webportal for review.

Topics for Discussion

Antipsychotic Medications in Children – The DUR Board reviewed Antipsychotic Medications in Children reports for FFS and MCOs.

Antidepressant Medications in Children – The DUR Board reviewed Antidepressant Medications in Children reports for FFS and MCOs.

Mood Stabilizer Medications in Children – The DUR Board reviewed Mood Stabilizer Medications in Children reports for FFS and MCOs.

Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children – The DUR Board reviewed Overlaps in Antipsychotics, Antidepressants and Mood

Stabilizers in Children reports for FFS and MCOs. The DUR Board is interested in seeing if other types of therapies such as behavioral therapies can be included in this report. This will be researched to see if this type of information can be pulled into the report.

Reports

ProDUR

The DUR Board reviewed and discussed the ProDUR reports. The DUR Board reviewed the new ProDUR Top Encounters by Problem Type – Severity 2 and Severity 3 reports. A list showing the possible ProDUR edits to turn off will be created internally and presented at a future DUR meeting.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports. The report showing the summary of the RetroDUR activity responses will be brought back into future binders. The DUR Board requested a future re-review be done on a recent RetroDUR activity on Atypical Antipsychotics without Metabolic Testing. The RetroDUR activity response page, along with the RetroDUR letter, will be included in future DUR binders.

II. RetroDUR Criteria Estimates

The DUR Board reviewed the Criteria Exception Estimates Reports. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for FFS and each individual MCO plan.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. The board requested to identify and label the preferred and non-preferred drugs on the Top 25 Drugs Ranked reports.

Closing Comments

Dr. Cain mentioned that there are two physician vacancies on the DUR Board.

Next DUR Meeting

June 13, 2024
Meeting adjourned at 3:32 pm.